Latest Psychedelic Medicine News

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

Entropy Neurodynamics has successfully dosed all six participants in the first cohort of its Phase 2 trial for TRP-8803, an intravenous psilocin therapy targeting Binge Eating Disorder. The study demonstrated controlled psychedelic responses, setting the stage for a Data and Safety Monitoring Board review and topline results expected in July 2026.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.